|
Market Closed -
Nasdaq
01:30:00 17/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 62.23 USD | -0.95% |
|
+3.96% | +41.98% |
| 09/10 | Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says | MT |
| 09/10 | RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating | MT |
Main competitors
| Change | 5-day change | 1-month change | 3-month change | YTD change | 1-year change | 3-year change | 5-year change | 10-year change | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | -0.95% | +3.96% | +9.60% | +11.76% | +41.98% | +58.71% | +188.50% | +185.20% | +449.73% | 1.54TCr | |
| -6.60% | -8.56% | -8.50% | +13.62% | +59.20% | +42.79% | +64.16% | -0.71% | - | 6.5TCr | |
| -4.09% | -0.11% | -14.26% | -3.01% | +1.51% | +2.31% | +54.81% | +185.00% | +4,786.50% | 5.12TCr | |
| +0.03% | +5.56% | +12.18% | +5.01% | +12.31% | +10.18% | +41.75% | -16.32% | +231.87% | 5.12TCr | |
| -1.53% | +2.70% | -0.71% | +26.80% | +18.41% | +29.72% | +34.13% | +7.25% | +254.26% | 4.39TCr | |
| -1.34% | +4.12% | +6.03% | +16.27% | +21.48% | +16.05% | +112.18% | +2.97% | +1,070.88% | 4.2TCr | |
| -5.97% | -6.22% | -9.17% | -0.68% | +123.43% | +258.21% | +421.57% | +560.33% | - | 3.81TCr | |
| +6.53% | +8.02% | +9.48% | +10.35% | +12.54% | +15.74% | +53.94% | +7.26% | +169.34% | 3.32TCr | |
| -0.90% | -10.49% | -3.48% | +22.58% | +53.31% | +31.48% | -1.63% | -55.94% | - | 2.52TCr | |
| -2.76% | -9.54% | -8.47% | -4.20% | -7.87% | -16.53% | -9.55% | -64.59% | - | 2.2TCr | |
| -1.07% | +2.33% | +13.16% | +32.35% | +23.43% | +17.24% | +11.20% | -12.27% | +122.80% | 2.25TCr | |
| -2.96% | -4.30% | -21.46% | -10.41% | -44.69% | -41.01% | +283.85% | +263.42% | +600.66% | 2.1TCr | |
| -1.61% | +1.05% | +0.33% | +14.97% | +10.12% | +18.66% | +160.66% | +230.59% | +2,018.05% | 1.73TCr | |
| +3.32% | +4.18% | +3.32% | -1.19% | +193.84% | +167.13% | +381.95% | +1,614.31% | +817.72% | 1.59TCr | |
| -1.14% | +1.48% | +4.77% | +12.60% | +25.42% | +23.28% | +55.28% | -27.90% | +87.27% | 1.53TCr | |
| -0.60% | -1.74% | -9.06% | -13.30% | - | - | - | - | - | 1.48TCr | |
| -1.99% | -0.54% | +9.78% | +30.98% | +50.47% | +71.56% | +55.73% | -25.62% | +272.63% | 1.43TCr | |
| -2.83% | +3.66% | -2.16% | +0.11% | -6.61% | -9.70% | -30.58% | -38.13% | +120.84% | 1.31TCr | |
| +3.10% | +1.66% | -1.87% | -13.49% | +15.25% | -4.52% | +456.65% | - | - | 1.38TCr | |
| -9.01% | -8.76% | -7.50% | +20.77% | +9.60% | -28.89% | - | - | - | 1.17TCr | |
| Average | -1.62% | -0.39% | -0.90% | +8.59% | +32.27% | +34.86% | +129.70% | +165.58% | +846.35% | 2.73TCr | |
| Weighted average by Cap. | -1.98% | -0.59% | -1.39% | +9.27% | +32.69% | +38.46% | +112.28% | +126.86% | +1,110.12% |
- Stock Market
- Stocks
- EXEL Stock
- Sector Exelixis, Inc.
Select your edition
All financial news and data tailored to specific country editions
